Abstract: Since the outbreak of SARS-CoV-2, there are many variants. FineTest has developed some SARS-CoV-2 related antibodies and proteins for research use only.
Keywords: SARS-CoV-2, COVID-19, Anti Spike Antibodies, Nucleocapsid Antibodies, Spike Protein, Spike Glycoprotein, Nucleoprotein
1. Overview of SARS-CoV-2
SARS-CoV-2 is a RNA virus which has a high mutation frequency of about three per million during virus replication. In other words, one in every 10 viruses may mutate. Thus, the appearance of new variant is normal.
Based on the criticality, variants of SARS-CoV-2 are classified as two types by WHO: variant of concern(VOC) and variant of interest (VOI). VOC causes many SARS-CoV-2 cases in the world and many data have shown its transmissibility, strong toxicity and reduction of curative effect in vaccine or clinical treatment. VOI causes community cases or appears in many countries. But mass infection doesn't appear. Currently, VOC has a great influence and threat on epidemic situation, including Alpha, Beta, Gamma, Delta, Omicron.
2. Omicron Variant(B.1.1.529)
In 2021, Omicron (B.1.1.529) is initially detected in a South African case sample. The variant has a rapid increase in two weeks and is identified as the variant of concern(VOC) by WHO. See the comparison of mutation sites between five variants.
Figure Source: Zoonoses, 2021, DOI: 10.15212/ZOONOSES-2021-0024.
There are 50 mutations in B.1.1.529. Spike protein has 32 mutations. It's reported that the mutation of Omicron is twice as Delta. Especially, H655Y, N679K and P681H can easily help virus enter human body.
Figure Source: COVID-19 Genomics UK (COG-UK) Consortium.
3. FineTest SARS-CoV-2 Antibodies and Proteins
Nucleoprotein Products | |
P3003 | Recombinant SARS-CoV-2 Nucleoprotein |
P2908 | Recombinant SARS-CoV-2 Nucleoprotein [Delta B.1.617.2] |
P8341 | Recombinant SARS-CoV-2 Nucleoprotein [Omicron B.1.1.529] |
FNab10308 | anti- 2019 nCOV N protein antibody |
FNab10309 | anti- 2019 nCOV N protein antibody |
Spike Proteins Products | |
P3006 | Recombinant SARS-CoV-2 Spike Glycoprotein RBD |
P3018 | Recombinant SARS-CoV-2 Spike Glycoprotein |
P8342 | Recombinant SARS-CoV-2 Spike Glycoprotein RBD [Omicron B.1.1.529] |
FNab10400 | anti- 2019 nCOV S1 protein antibody |
FNab10528 | anti- 2019 nCOV S1 protein antibody |
REFERENCES
[1] Mechanisms of SARS-CoV-2 Transmission and Pathogenesis, PMID: 33132005.
[2] From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses, PMID: 32798769.